Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
This article was originally published in The Pink Sheet Daily
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.
You may also be interested in...
Weeks after immuno-oncology tie-up with Sanofi, Evotec signs a collaboration in fibrotic disease with Pfizer. Epirus expands its biosimilars capabilities with the acquisition of Dutch biotech Bioceros.
Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.
Italy strengthens future role in pharmaceutical manufacturing by the purchase of Merck & Co.’s high-profile Pavia facility by a local company.